Selective inhibitors for cyclin-dependent kinases

US8067424B2 · kind B2 · utility

Assignees

• EMORY UNIVERSITY · US
• Imperial College of Science and Technology · GB

Inventors

• Ashutosh S. Jogalekar · Redwood City, US
• James P. Snyder · Atlanta, US
• Dennis C. Liotta · Atlanta, US
• Anthony Barrett · London, GB
• Raoul C. Coombes · London, GB
• Simak Ali · London, GB
• Aleksandra Siwicka · Warszawa, PL
• Jan Brackow · Suhr, CH
• Bodo Scheiper · Frankfurt am Main, DE

Key dates

• Filing date: Dec 4, 2009
• Grant date: Nov 29, 2011
• Expiry date: Dec 4, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.